
Claims

1. A compound of 2-[4-(2-methyl-4-pyridyl)pyrrolo[3,2-c]pyridin-1-yl]-N-(5-pyrazin-2-yl-2-pyridyl)acetamide (AZD5055):



for use in treating interstitial lung disease in a subject in need thereof, wherein a dose of between 5 and 35 mg per day is to be administered orally to the subject.

2. The compound for use according to claim 1, wherein the dose per day is between 10 and 30 mg per day.

3. The compound for use according to either claim 1 or claim 2, wherein the dose per day is between 15 and 25 mg per day.

4. The compound for use according to claim 1, wherein the dose per day is 5mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg or 35mg per day.

5. The compound for use according to claim 1, wherein the dose per day is selected from the group consisting of: 5mg, 6mg, 7mg, 8mg, 9mg, 10mg, 11mg, 12mg, 13mg, 14mg, 15mg, 16mg, 17mg, 18mg, 19mg, 20mg, 21mg, 22mg, 23mg, 24mg, 25mg, 26mg, 27mg, 28mg, 29mg, 30mg, 31mg, 32mg, 33mg, 34mg and 35mg.

6. The compound for use according to claim 1, wherein the dose per day is about 5 mg per day.

7. The compound for use according to claim 1, wherein the dose per day is about 15 mg per day.

8. The compound for use according to any one of claim 1 to 7, wherein AZD5055 is to be administered once a day (QD).

9. The compound for use according to any one of claim 1 to 7, wherein AZD5055 is to be administered twice a day (BID).

10. The compound for use according to any one of claims 1 to 9, wherein AZD5055 is to be continuously administered in a treatment cycle.

11. The compound for use according to any one of claims 1 to 10, wherein AZD5055 is taken on an empty stomach, with no food two hours before, and one hour after.

12. The compound for use according to any one of claims 1 to 10, wherein AZD5055 is taken with food.


13. The compound for use according to any one of claims 1 to 12, which additionally comprises the separate, sequential or simultaneous administration of a proton pump inhibitor or a pharmaceutically acceptable salt thereof.

14. The compound for use according to claim 13, wherein the proton pump inhibitor is rabeprazole.

15. The compound for use according to claim 14, wherein rabeprazole is to be administered in a dose of about 10 or 20 mg orally twice a day (BID).

16. The compound for use according to any one of claims 1 to 15, wherein the interstitial lung disease is idiopathic pulmonary fibrosis.

17. An oral dosage unit which comprises 2-[4-(2-methyl-4-pyridyl)pyrrolo[3,2-c]pyridin-1-yl]-N-(5-pyrazin-2-yl-2-pyridyl)acetamide (AZD5055):



in an amount of between 2.5 and 35 mg.

18. The oral dosage unit according to claim 17, which comprises the daily dose of AZD5055 as defined in any of claims 1 to 7.

19. The oral dosage unit according to claim 17, which comprises half the daily dose of AZD5055 as defined in any of claims 1 to 7.

20. The oral dosage unit according to any one of claims 17 to 19, wherein the oral dosage unit is an aqueous suspension.

21. The oral dosage unit according to claim 20, wherein the suspension comprises one or more additional excipients selected from the group consisting of: viscosity agents, sweeteners and colorants.

22. The oral dosage unit according to any one of claims 17 to 19, wherein the oral dosage unit is a tablet.

23. The oral dosage unit according to claim 22, wherein the tablet comprises one or more pharmaceutical excipients selected from the group consisting of: diluents, compression aids, disintegrants, and glidants/lubricants.

24. The oral dosage unit according to claim 23, wherein a diluent is present, and the diluent is a sugar or sugar-containing, except mannitol, or an inorganic compound.

25. The oral dosage unit according to claim 24, wherein, the diluent is microcrystalline cellulose.

26. The oral dosage unit according to any one of claims 23 to 25, wherein a compression aid is present, and is selected from microcrystalline cellulose (MCC), xylitol, di-calcium phosphate, lactose monohydrate and starch.

27. The oral dosage unit according to claim 26, wherein the compression aid is di-calcium phosphate.

28. The oral dosage unit according to either claim 26 or claim 27, wherein the compression aid is between 10 and 30 wt% of the tablet core.

29. The oral dosage unit according to any one of claims 23 to 28, wherein a lubricant/glidant is present and is glyceryl behenate.

30. The oral dosage unit according to claim 29, wherein the lubricant/glidant is between 2 and 15 wt% of the tablet core.

31. The oral dosage unit according to any one of claims 23 to 30, wherein a disintegrant is present, and is a compound which swells or dissolves in water.

32. The oral dosage unit according to claim 31, wherein the disintegrant is croscarmellose sodium.

33. The oral dosage unit according to either claim 31 or claim 32, wherein the disintegrant is between 2 and 15 wt% of the tablet core.

34. The oral dosage unit according to any one of claims 23 to 33, wherein the tablet is coated.